<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38008902</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1445-5994</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Internal medicine journal</Title><ISOAbbreviation>Intern Med J</ISOAbbreviation></Journal><ArticleTitle>The lingering symptoms of post-COVID-19 condition (long-COVID): a prospective cohort study.</ArticleTitle><Pagination><StartPage>224</StartPage><EndPage>233</EndPage><MedlinePgn>224-233</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/imj.16251</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Longer-term symptoms (long COVID) may be present in seemingly recovered patients for several months and can be debilitating.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the prevalence and type of symptoms in those with a prior COVID-19 diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective, longitudinal observational study commenced in July 2020 investigating the longer-term health impacts of COVID-19. Participants were recruited via public health units and media publicity. Surveys were completed upon enrolment, and at 1, 3, 6 and 12 months. Outcome measures included incidence of activity limitations and symptoms against health and vaccination status, age and gender.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 339 participants were recruited. At 3 months after COVID-19, 66.8% reported symptoms, and 44.8% were still experiencing symptoms at 12 months. Fatigue was most common at every point (between 53.1% and 33.1%). Pain symptoms increased in relative prevalence over time, whereas respiratory/pulmonary-type symptoms decreased substantially after 3 months. Females and younger people were more likely to experience symptoms in the early stages of long COVID (P &lt;&#x2009;0.01) and those with more comorbidities in the latter stages (P &lt;&#x2009;0.001). Vaccination showed a statistically significant protective effect against symptoms (P &lt;&#x2009;0.01-0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long-term COVID-19 symptoms exist among recovered patients up to 12 months after contracting the virus. Fatigue is a primary contributor, while chronic pain became more problematic after 6 months. Vaccination was a factor in preventing long-term symptoms and aiding faster recovery from symptoms. Further work exploring additional contributors to symptom prevalence would assist in developing appropriate follow-up care.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Internal Medicine Journal published by John Wiley &amp; Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6395-9364</Identifier><AffiliationInfo><Affiliation>Physician in Trauma and Rehabilitation Medicine, Illawarra Shoalhaven Local Health District, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Senior Staff Specialist, Wollongong Hospital, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pryor</LastName><ForeName>Anna J G</ForeName><Initials>AJG</Initials><AffiliationInfo><Affiliation>Research Central, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melville</LastName><ForeName>Geoffrey W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Research Central, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Research Central, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Lyndel</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1442-706X</Identifier><AffiliationInfo><Affiliation>Research Central, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Kimberley J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0002-7835-7259</Identifier><AffiliationInfo><Affiliation>Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Central, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Intern Med J</MedlineTA><NlmUniqueID>101092952</NlmUniqueID><ISSNLinking>1444-0903</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059350" MajorTopicYN="Y">Chronic Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID complications</Keyword><Keyword MajorTopicYN="N">COVID symptoms</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38008902</ArticleId><ArticleId IdType="doi">10.1111/imj.16251</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>World Health Organization. WHO coronavirus (COVID-19) dashboard. 2023 [viewed 2023 September 7]. Available from URL: https://covid19.who.int/</Citation></Reference><Reference><Citation>Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep 2021; 11: 13153.</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022; 226: 1593-1607.</Citation></Reference><Reference><Citation>World Health Organisation. A clinical case definition of post COVID-19 condition by a Delphi consensus [Internet]. 2021 [accessed 05/01/2023]. Available from URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023 Mar; 21: 133-146.</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-232.</Citation></Reference><Reference><Citation>Australian Institute of Health and Welfare. Long COVID in Australia - a review of the literature. Canberra, Australia: AIHW; 2022 catalogue number PHE 318.</Citation></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 2022; 377: e069676.</Citation></Reference><Reference><Citation>Australian Government Department of Health and Aged Care, Coronavirus (COVID-19) - CDNA National Guidelines for Public Health Units, 2023 [accessed 08/09/2023]. Available from URL: https://www.health.gov.au/resources/publications/coronavirus-covid-19-cdna-national-guidelines-for-public-health-units</Citation></Reference><Reference><Citation>Tan S, Hewitt L, Cuenca J, Risi D. Outcomes of COVID-19 in the community. A prospective cohort study. Aust J Gen Pract 2021; 50: 922-928.</Citation></Reference><Reference><Citation>The jamovi project (2022). jamovi. (Version 2.3) (Computer Software). Retrieved from URL: https://www.jamovi.org</Citation></Reference><Reference><Citation>R Core Team (2021). R: a language and environment for statistical computing. (Version 4.1) (Computer software). Retrieved from URL: https://cran.r-project.org</Citation></Reference><Reference><Citation>Yule G. On the methods of measuring the association between two variables. The first identification of the phi-coefficient. J R Stat Soc 1912; 75: 579.</Citation></Reference><Reference><Citation>Cockburn P. How NSW's COVID-19 outbreak grew from one limo driver to more than 300 cases. ABC News 2021, (cited 2023 Jan 6). Available from URL: https://www.abc.net.au/news/2021-07-07/nsw-covid-19-outbreak-explained/100271128.</Citation></Reference><Reference><Citation>Kaye B. Australia records first Omicron community case, authorities hold nerve for now. Reuters. 2021. Available from URL: https://www.reuters.com/world/asia-pacific/australia-records-first-omicron-community-case-authorities-hold-nerve-now-2021-12-03/</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al. Attributes and predictors of long COVID. Nat Med 2021; 27: 626-631.</Citation></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021; 27: 258-263.</Citation></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 2021; 4: e2111417.</Citation></Reference><Reference><Citation>Tortajada C, Navarro A, Andreu-Ballester JC, Mayor A, A&#xf1;&#xf3;n S, Flores J. Prevalence and duration of symptoms among moderate and severe COVID-19 patients 12 months after discharge. Intern Emerg Med 2022; 17: 929-934.</Citation></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019.</Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022; 22: 43-55.</Citation></Reference><Reference><Citation>Australian National Audit Office. Australia's COVID-19 vaccine rollout (Internet). Canberra: Australian National Audit Office; August 2022 (cited 2023 Jan 6); Available from URL: https://www.anao.gov.au/work/performance-audit/australia-covid-19-vaccine-rollout.</Citation></Reference><Reference><Citation>Fedorowski A, Sutton R. Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome. Nat Rev Cardiol 2023; 20: 281-282.</Citation></Reference><Reference><Citation>Seeley MC, Gallagher C, Ong E, Langdon A, Chieng J, Bailey D et al. High incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long COVID: implications for management and health care planning. Am J Med 2023 (in press). https://doi.org/10.1016/j.amjmed.2023.06.010.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>